CONTEXT: The lack of knowledge of the accurate conversion ratio (CR) between intravenous (IV) and oral hydromorphone and opioid rotation ratio (ORR) between IV hydromorphone and oral morphine equivalent daily dose (MEDD) may lead to poorly controlled pain or overdosing in cancer inpatients. OBJECTIVES: We aimed to determine the CR and ORR from IV hydromorphone to oral hydromorphone and MEDD (obtained from oral morphine and oxycodone). METHODS: A total of 4745 consecutive inpatient palliative care consults during 2010-14 were reviewed for conversions from IV hydromorphone to oral hydromorphone, morphine or oxycodone. Patient characteristics, symptoms, and opioid doses were determined in patients successfully discharged on oral opioids without readmission within one week. Linear regression analysis was used to estimate the CR or ORR between the 24 hour IV hydromorphone mg dose before conversion and the oral opioid mg dose used before discharge. RESULTS: Among 394 patients on IV hydromorphone, 147 underwent conversion to oral hydromorphone and 247 underwent rotation to oral morphine (163) or oxycodone (84). The median (interquartile range) CR from IV to PO hydromorphone was 2.5 (2.14-2.75) with correlation of 0.95 (P < 0.0001). The median ORR (interquartile range) from IV hydromorphone to MEDD was 11.46 (9.84-13.00) with correlation of 0.93(P < 0.0001). The median ORR was 11.54 in patients receiving <30 mg of IV hydromorphone/day and 9.86 in patients receiving ≥30 mg (P = 0.0004). CONCLUSION: Our study found that 1 mg of IV hydromorphone is equivalent to 2.5 mg of oral hydromorphone and 11.46 mg of MEDD. Hydromorphone at doses ≥30 mg/day may require a lower ORR to other opioids.
CONTEXT: The lack of knowledge of the accurate conversion ratio (CR) between intravenous (IV) and oral hydromorphone and opioid rotation ratio (ORR) between IV hydromorphone and oral morphine equivalent daily dose (MEDD) may lead to poorly controlled pain or overdosing in cancer inpatients. OBJECTIVES: We aimed to determine the CR and ORR from IV hydromorphone to oral hydromorphone and MEDD (obtained from oral morphine and oxycodone). METHODS: A total of 4745 consecutive inpatient palliative care consults during 2010-14 were reviewed for conversions from IV hydromorphone to oral hydromorphone, morphine or oxycodone. Patient characteristics, symptoms, and opioid doses were determined in patients successfully discharged on oral opioids without readmission within one week. Linear regression analysis was used to estimate the CR or ORR between the 24 hour IV hydromorphone mg dose before conversion and the oral opioid mg dose used before discharge. RESULTS: Among 394 patients on IV hydromorphone, 147 underwent conversion to oral hydromorphone and 247 underwent rotation to oral morphine (163) or oxycodone (84). The median (interquartile range) CR from IV to PO hydromorphone was 2.5 (2.14-2.75) with correlation of 0.95 (P < 0.0001). The median ORR (interquartile range) from IV hydromorphone to MEDD was 11.46 (9.84-13.00) with correlation of 0.93(P < 0.0001). The median ORR was 11.54 in patients receiving <30 mg of IV hydromorphone/day and 9.86 in patients receiving ≥30 mg (P = 0.0004). CONCLUSION: Our study found that 1 mg of IV hydromorphone is equivalent to 2.5 mg of oral hydromorphone and 11.46 mg of MEDD. Hydromorphone at doses ≥30 mg/day may require a lower ORR to other opioids.
Authors: Rosa Rodriguez-Monguio; Zhixin Lun; Tasce Bongiovanni; Catherine L Chen; Enrique Seoane-Vazquez Journal: Drug Saf Date: 2022-03-17 Impact factor: 5.228
Authors: Alberto Bongiovanni; Flavia Foca; Devil Oboldi; Danila Diano; Alberto Bazzocchi; Laura Fabbri; Laura Mercatali; Silvia Vanni; Marco Maltoni; David Bianchini; Carla Casadei; Federica Matteucci; Oriana Nanni; Benedetta Rossi; Emanuele Sintuzzi; Maria Elena Martoni; Venetia Zavoiu; Domenico Barone; Mattia Altini; Toni Ibrahim Journal: Support Care Cancer Date: 2022-03-24 Impact factor: 3.603
Authors: D Harding; S L Giles; M R D Brown; G R Ter Haar; M van den Bosch; L W Bartels; Y-S Kim; M Deppe; N M deSouza Journal: Clin Oncol (R Coll Radiol) Date: 2018-01-06 Impact factor: 4.126
Authors: Sharon L Giles; Matthew R D Brown; Ian Rivens; Martin Deppe; Merel Huisman; Young-Sun Kim; Paul Farquhar-Smith; John E Williams; Gail R Ter Haar; Nandita M deSouza Journal: J Vasc Interv Radiol Date: 2019-05-14 Impact factor: 3.464
Authors: Heather Carmichael; Franklin L Wright; Robert C McIntyre; Thomas Vogler; Shane Urban; Sarah E Jolley; Ellen L Burnham; Whitney Firth; Catherine G Velopulos; Juan Pablo Idrovo Journal: Trauma Surg Acute Care Open Date: 2021-01-19